Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001189 · ClinicalTrials.gov registry record · Phase 2
The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00001189: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001189 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001189, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Patients with Grade I soft tissue sarcomas or benign, non-metastasizing invasive soft tissue tumors will receive wide local excision and be prospectively randomized as to either receive or not receive radiation therapy.
Interventions
- PROCEDURE radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1983-12 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001189
The ClinicalTrials.gov registry entry for NCT00001189 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which radiotherapy is the first listed.
NCT00001189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001189 about?
NCT00001189 is a clinical study titled "The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors". Patients with Grade I soft tissue sarcomas or benign, non-metastasizing invasive soft tissue tumors will receive wide local excision and be prospectively randomized as to either receive or not receive radiation therapy.
What is the current status of trial NCT00001189?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 1983-12. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00001189?
The interventions under investigation include: radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00001189?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.